Treatment of non-alcoholic fatty liver disease
CA 2489323 A1 · Owner: Boylan, Michael O. · Inventors: Boylan, Michael O.; Wolfe, M. Michael
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention concerns the use of various forms of GIP-receptor antagonists to attenuate the insulin response to GIP following meals in animals, such as humans, to prevent, reduce inhibit and/or treat nonalcoholic , fatty liver disease by virtue of its prevention and/or reversal of hyperinsulinemia and insulin resistance. Thus the use of the GIP-receptor , antagonists in any effective form is believed to prevent the development and reverse the process of NAFLD. The present invention is accomplished by administering an effective amount of an antagonistic agent such as a GIP , antagonist or an antisense molecule to antagonize, block, inhibit or ablate the receptor to …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 13, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 13, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 13, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.